ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

be considered in three groups: the more frequent gastrinomas and insulinomas considered independently and all the rare F-P-NETs (RFTs) considered together and as a separate category (Appendix 1 and table